Learning Center Home
Educational Content
Search
Contact Us
IBMS Home
BoneKEy
IBMS Davos Workshops: Bone Biology & Therapeutics
Session List
Click
here
to search this conference.
Display sessions grouped by:
Track
Session Code
Speaker
Date
Track
:
Opening Ceremony
Invited Lectures - Cell Biology: Recent Advances in Biology
Invited Lectures - Cell Biology 2
Invited Lectures - Cell Biology 3
Invited Lectures - Cell Biology 4
Oral Presentations - Cell Biology: Osteoblasts (A)
Invited Lectures - Cell Biology 5
Invited Lectures - Cell Biology 6
Oral Presentations - Cell Biology: Osteoclasts
OralPresentations - Cell Biology: Skeletal Metabolism
Invited Lectures - Cell Biology 7
Invited Lectures - Translational 1
Invited Lectures - Translational 2
Invited Lectures - Translational: Wnt Pathway
Oral Presentations - Translational
Invited Lectures - Translational 5
Satellite Symposium - Cathepsin K: A New Therapeutic Target sponsored by Merck & Co., Inc.
Invited Lectures - Bone Therapeutics 1
Oral Presentations - Bone Therapeutics (A)
Satellite Symposium - Bisphosphonates for Patients with Breast Cancer and Bone Metastases - Current Controversies sponsored by F. Hoffman-LaRoche LTD
Satellite Symposium - The Role of the RANK/RANK Ligand/OPG Pathway in Pathological Bone Loss sponsored by Amgen, Inc.
Invited Lectures - Bone Therapeutics 2
Invited Lectures - Bone Therapeutics 3
Satellite Symposium - Bisphosphonate Mechanism of Action: Application to Understanding Potential Clinical Differentiation sponsored by The Alliance for Better Bone Health
Oral Presentations - Bone Therapeutics (B)
Invited Lectures - Bone Therapeutics 4 sponsored by an unrestricted educational grant from Novartis Oncology
Closing Remarks
Interview Sessions
Opening Ceremony
010 Opening Ceremony: Welcome
015 Presentation of Gideon & Sevgi Rodan IBMS Fellowship
020 Tribute to Herbie Fleisch
Back to Top
Invited Lectures - Cell Biology: Recent Advances in Biology
040 Hematopoietic Stem Cells and their Microenvironment
Back to Top
Invited Lectures - Cell Biology 2
060 The Role of Osteocytes in Bone and Mineral Metabolism
Back to Top
Invited Lectures - Cell Biology 3
080 Paradoxes in Osteoclast Biology
Back to Top
Invited Lectures - Cell Biology 4
100 Regulation of Osteoclastogenesis and Osteoimmunology
Back to Top
Oral Presentations - Cell Biology: Osteoblasts (A)
060-01 ERK1/2 and Fra-1 Mediate Phosphate-Dependent Stimulation of Matrix Gla Protein Expression in Osteoblasts (16)
060-02 TGF2 Beta Protects Osteoblast Apoptosis Induced by Mechanical Unloading by Targeting PI3K/Akt/Bad Signaling In Vivo (8)
060-03 Regulation of Mitogen-Activated Protein Kinase Phosphatase-1 by PTH/PTHrP Involves cAMP and PKC Pathways in Differentiated Osteoblasts (18)
060-04 Snail, a Transcription Factor, Plays a Crucial Role during Osteogenic Differentiation by Acting as a Direct Repressor of Runx2 (28)
060-05 Lack of Oxytocin Retards Osteoblast Differentiation and Bone Formation (5)
060-06 Stage-Specific Subsets of Perichondrial Osteoblasts Differentially Relate to Endothelium and Bone and Display Different Destinations in Development (21)
060-07 Dkk1 Is a Possible Direct Target of Osx (40)
060-08 Inactivation of the Integrin-Linked Kinase (ILK) in Osteoblasts Increases Mineralization (9)
060-09 Lactoferrin, a Regulator of Bone — Mechanisms of Action (6)
060-10 Cannabinoid Receptor 2 Selective Agonists Stimulate Osteoclast Formation In Vitro but Act as Anabolic Agents In Vivo by Stimulating Bone Formation (34)
Back to Top
Invited Lectures - Cell Biology 5
120 Role of Oxidative Stress in Bone Health and Disease
Back to Top
Invited Lectures - Cell Biology 6
130 Osteogenic-Angiogenic Coupling
Back to Top
Oral Presentations - Cell Biology: Osteoclasts
090-1 Id1 Negatively Regulates Osteoclast Differentiation and Maintains Hematopoietic Stem Cell Niche Homeostasis (43)
090-2 Sex Steroids Hormone Mediate Osteoprotecitve Effects by Controlling Osteoclast Life Cycle (48)
090-3 TRPV4-Mediated Calcium Influx Regulates Terminal Differentiation of Osteoclasts (51)
090-4 Zoledronic Acid-Induced IPP/ApppI Formation In Vivo and In Vitro (50)
090-5 The Matrix Proline/Arginine-Rich End Leucin-Rich Repeat Protein (PRELP) Impairs Osteoclastogenesis by Inhibiting NF-kappaB Activity (52)
090-6 Poster Viewing - Poster Numbers 56 - 110
Back to Top
OralPresentations - Cell Biology: Skeletal Metabolism
100-1 The Aging Associated Gene SIRT-1 Controls Bone Mass In Vivo Through Osteoblast and Osteoclast Regulation (73)
100-2 Endorphins Regulate Bone Homeostasis by Actions through Dynorphin (60)
100-3 Mice Treated with a Myostatin/GDF-8 Decoy Receptor, ActRIIB-Fc, Exhibit a Tremendous Increase in Bone Mass (66)
100-4 Effect of a Selective p38alpha Inhibitor on Trabecular Bone Loss Induced by Estrogen Deficiency (69)
100-5 A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone (57)
100-6 Loss of the Vitamin D Receptor in the Intestine Induces Severe Bone Loss To Preserve Normal Calcemia (91)
100-7 Osteogenic Differentiation of Marrow Cells in Response to Hedgehog Stimulation In Vivo (78)
100-8 Effects of Global Knockout or Over-Expression of Fibroblast Growth Factor-2 in Osteoblasts on Fracture Healing in Transgenic Mice (107)
Back to Top
Invited Lectures - Cell Biology 7
160 Skeletal Regulation of Energy Metabolism
Back to Top
Invited Lectures - Translational 1
170 Novel Imaging Techniques in Laboratory Bone Research
180 Advances in the Clinical Imaging of Bone
190 Fracture Surrogates in Osteoporosis
Back to Top
Invited Lectures - Translational 2
200 Biology of Fracture Healing and Effect of Osteoporosis Therapies
210 Osteoarthritis and Osteoporosis: a Molecular Basis for an Inverse Relationship
Back to Top
Invited Lectures - Translational: Wnt Pathway
220 Regulation of WNT Signalling at the Plasma Membrane
Back to Top
Oral Presentations - Translational
140-01 PTH-Induced Bone Anabolism Is Blunted in SOST Overexpressing Mice (88)
140-02 The High Bone Mass Phenotype of SOST Deficient Mice Is Characterized by Progressive Increase in Bone Thickness, Mineralization and Predicted Cortical Bone Strength in a Gene Dosage Unrelated Manner (89)
140-03 Gender-Specific Control of Peak Bone Mass by the Wnt Pathway: Androgen Signaling Protects Against Lef1 Haploinsufficiency-Induced Bone Loss (75)
140-04 Surprising Lifetime Effects of Deletion of the Mouse Calcitonin Gene (76)
140-05 Erythropoietin: A Novel DABA? (100)
140-06 Differing Effects of Pre and Post-Fracture Bisphosphonate Treatment on Bone Repair in Estrogen-Deficient Rats (136)
140-07 Enhanced Expression of BMP2/Smad Pathway and SP7 by Statins during Fracture Repair (125)
140-08 Evaluation of the Relative Mineral-Binding Affinities of Clinically-Relevant Bisphosphonates by Using Hydroxyapatite-Column Chromatography and Adsorption Isotherms Combined with Mass Spectrometric Analysis (162)
140-09 Structure Activity Relationships of Nitrogen Containing Bisphosphonates Which Induce Conformational Changes in Farnesyl Pyrophosphate Synthase (119)
140-10 Treatment with RAP-011 (A Soluble Activin Receptor Type IIA) Increases Bone Mineral Density in Mice with Prior Bisphosphonate Exposure (144)
Back to Top
Invited Lectures - Translational 5
270 Regulation of Endogenous Levels of PTH by Calcilytic Compounds
290 PTH as a Bone Anabolic — Future Directions
Back to Top
Satellite Symposium - Cathepsin K: A New Therapeutic Target sponsored by Merck & Co., Inc.
600 Discovery of a Selective Cathepsin K Inhibitor - part of a Satellite Symposium sponsored by Merck & Co., Inc.
610 Preclinical Studies with Odanacatib - part of a Satellite Symposium sponsored by Merck & Co., Inc.
620 Clinical Development of Odanacatib for the Treatment of Osteoporosis - part of a Satellite Symposium sponsored by Merck & Co., Inc.
Back to Top
Invited Lectures - Bone Therapeutics 1
340 New Mechanisms for Old Targets: Novel Approaches to Stereoid Receptors in Drug Discovery
350 Cathepsin K Inhibitors: From the Bench to the Clinic
360 SERMs - What is Their Clinical Potential
370 Estrogen - Does it Still Have a Role?
Back to Top
Oral Presentations - Bone Therapeutics (A)
170-01 A Randomized, Double-Blind, Placebo-Controlled Study of a Cathepsin-K Inhibitor in the Treatment of Postmenopausal Women with Low BMD: 18-Month Results (126)
170-02 Short-Time Zoledronic Acid Pretreatment Stimulates Osteogenic Differentiation of Human Mesenchymal Stem Cells (120)
170-03 Bone Mineral Density and Biochemical Marker Response Rates in Postmenopausal Women after Treatment with Zoledronic Acid (115)
170-04 Inhibition of Osteoblast Function by Bisphosphonates (143)
170-05 Comparison of Bone Architecture Via Micro-CT after Long-Term Treatment with Risedronate and Alendronate: A Cross-Sectional Study in Women with Postmenopausal Osteoporosis (117)
170-06 Use of a Fluorescent Analogue of Risedronate To Study Localisation and Cellular Uptake of Bisphosphonates In Vivo (150)
170-07 In Vivo Effects of Zoledronic Acid on Peripheral γ/δ T Lymphocytes in Early Breast Cancer Patients (196)
170-08 Intravenous and Oral Ibandronate Are Equally Effective in Metastatic Bone Pain Reduction Regardless of Previous Bisphosphonate Treatment (176)
170-09 The Effect of Adjuvant Chemotherapy with a Taxane and a Bisphosphonate on Bone Mass and Bone Strength in an Animal Model (179)
170-10 Zoledronic Acid-Induced IPP Accumulation in Cancer Cells Strongly Correlates with Gammadelta T-Cell Mediated Cancer Cell Death (187)
Back to Top
Satellite Symposium - Bisphosphonates for Patients with Breast Cancer and Bone Metastases - Current Controversies sponsored by F. Hoffman-LaRoche LTD
390 From the Lab to the Clinic: Where are Bisphosphonates Going? - part of a Satellite Symposium sponsored by F.Hoffman-LaRoche LTD
400 Oral versus I.V. Bisphosphonates Efficacy: Is There a Compromise for Patients and Physicians? - part of a Satellite Symposium sponsored by F.Hoffman-LaRoche LTD
410 Is Renal Function Monitoring Necessary in Bisphosphonates Treatment? - part of a Satellite Symposium sponsored by F.Hoffman-LaRoche LTD
430 Use of Bone Markers in Malignancy - part of a Satellite Symposium sponsored by F.Hoffman-LaRoche LTD
600 Bisphosphonates for Patients with Breast Cancer and Bone Metastases: Current Controversies - Discussion - part of a Satellite Symposium sponsored by F.Hoffman-LaRoche LTD
Back to Top
Satellite Symposium - The Role of the RANK/RANK Ligand/OPG Pathway in Pathological Bone Loss sponsored by Amgen, Inc.
440 Update on RANK Ligand Inhibition in Pre-clinical Models of Bone Loss - part of a Satellite Symposium sponsored by Amgen, Inc.
445 Advances in Targeting the RANK/RANKL/OPG Pathway in Osteoporosis - part of a Satellite Symposium sponsored by Amgen, Inc.
460 RANK Ligand Inhibition in Cancer Patients: Current Status - part of a Satellite Symposium sponsored by Amgen, Inc.
Back to Top
Invited Lectures - Bone Therapeutics 2
470 Herbert Fleisch Memorial Lecture: Biphosphonates, Past, Present and Future
Back to Top
Invited Lectures - Bone Therapeutics 3
490 Therapy of Paediatric Bone Conditions
500 Pathogenesis and Managements of Paget's Disease
Back to Top
Satellite Symposium - Bisphosphonate Mechanism of Action: Application to Understanding Potential Clinical Differentiation sponsored by The Alliance for Better Bone Health
510 Connecting the Mechanistic Pharmacology of Bisphosphonates to Potential Clinical Differences - part of a Satellite Symposium sponsored by The Alliance for Better Bone Health
520 Evidence for Potential Similarities and Differences in Cellular & Skeletal Distribution of Bisphosphonates - part of a Satellite Symposium sponsored by The Alliance for Better Bone Health
530 The Osteocyte as a Potential Target Cell of Bisphosphonates and Role in Bone Strength - part of a Satellite Symposium sponsored by The Alliance for Better Bone Health
540 Evidence for Clinical Differentiation of Bisphosphonates - part of a Satellite Symposium sponsored by The Alliance for Better Bone Health
Back to Top
Oral Presentations - Bone Therapeutics (B)
230-1 Differential Effects of Host-Derived MMPs on Development of Multiple Myeloma In Vivo (169)
230-2 Farnesoid X Receptor in Primary Breast Carcinoma: A New Marker To Predict Bone Metastasis? (175)
230-3 Macrophage Inflammatory Protein (MIP)-3α/CCL20 and Its Receptor CCR6 Are Overexpressed in the Bone Microenvironment and Involved in Osteoclast Formation in Multiple Myeloma Patients: Potential Relationship With the Presence of Osteolytic Lesions (171)
230-4 Conditional Mouse Osteosarcoma, Dependent on p53 Loss and Potentiated by Loss of Rb, Mimics the Human Disease (202)
230-5 Antineoplastic Activity of Bone-Targeted Nanoparticles Loaded with Doxorubicin (195)
Back to Top
Invited Lectures - Bone Therapeutics 4 sponsored by an unrestricted educational grant from Novartis Oncology
560 The Premetastatic Niche
570 Mechanisms of Bone Metastasis and Novel Therapeutic Strategies
580 Overview of the Management of Bone Disease in Cancer Patients
Back to Top
Closing Remarks
590 Closing Remarks
Back to Top
Interview Sessions
01 Interview - Anke Roelofs - University of Aberdeen, Aberdeen, UK
02 Interview - Claire Edwards - Vanderbilt University, Nashville, Tennessee, USA
03 Interview - Gloria Gutierrez - Vanderbilt University Medical Center, Nashville, Tennessee, USA
04 Interview - Hannu Monkkonen - INSERM, Lyon, France
06 Interview - Ina Kramer - Novartis Institutes for BioMedical Research, Basel, Switzerland
07 Interview - Jad El-Hoss - Shriners Hospital for Children and McGill University, Montreal, Canada
08 Interview - Jillian Cornish - University of Auckland, Auckland, New Zealand
09 Interview - Peter Bialek - Wyeth Research, Cambridge, Massachusetts, USA
10 Interview - R. Scott Pearsall - Acceleron Pharma, Inc., Cambridge, Massachusetts, USA
11 Interview - Yuuki Imai - Osaka City University Graduate School of Medicine, Osaka, Japan
12-1 Professor Fleisch and the Davos Workshops Remembered - Graham Russell - University of Oxford, Oxford, UK
12-2 Professor Fleisch and the Davos Workshops Remembered - Francis Glorieux - Shriners Hospital for Children and McGill University, Montreal, Canada
12-3 Professor Fleisch and the Davos Workshops Remembered - Thomas John Martin - University of Melbourne, Melbourne, Australia
Back to Top